The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial

Statistically significant overall survival (OS) benefits of CDK4 and CDK6 inhibitors in combination with fulvestrant for hormone receptor (HR)-positive, ERBB2 (formerly HER2)-negative advanced breast cancer (ABC) in patients regardless of menopausal status after prior endocrine therapy (ET) has not...

Celý popis

Podrobná bibliografie

Vydáno v:	JAMA oncology Ročník 6; číslo 1; s. 116
Hlavní autoři:	Sledge, Jr, George W, Toi, Masakazu, Neven, Patrick, Sohn, Joohyuk, Inoue, Kenichi, Pivot, Xavier, Burdaeva, Olga, Okera, Meena, Masuda, Norikazu, Kaufman, Peter A, Koh, Han, Grischke, Eva-Maria, Conte, PierFranco, Lu, Yi, Barriga, Susana, Hurt, Karla, Frenzel, Martin, Johnston, Stephen, Llombart-Cussac, Antonio
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	United States 01.01.2020
Témata:	Aminopyridines - adverse effects Antineoplastic Combined Chemotherapy Protocols - adverse effects Benzimidazoles Breast Neoplasms - pathology Female Fulvestrant Humans Middle Aged Receptor, ErbB-2 Triple Negative Breast Neoplasms - drug therapy
ISSN:	2374-2445, 2374-2445
On-line přístup:	Zjistit podrobnosti o přístupu
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!